A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes
A global virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes
Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to announce the return of e-SPACE Heart Failure (HF) to be held 23-24 October 2026.
e-SPACE Heart Failure 2026 will once again offer high-quality, free virtual education – maximising global reach while delivering both international and regional perspectives. The expertly designed programme will delve into how leading clinicians are translating heart failure guidelines into real-world practice and will provide the latest insights into patient profiling for personalised heart failure therapy.
Building on the outstanding success of previous years, this event continues to unite TMA’s mission to deliver continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Driven by this shared expertise in educational programming and delivery and led by a world-renowned international faculty, e-SPACE Heart Failure 2026 is designed to help you achieve optimal clinical outcomes in heart failure management.
(Please note this programme is subject to change)
Day 1
Meet the Expert
Meet The Expert
Plenary Session
Session 1 - The 2026 Heart Failure Guidelines: What Will Change My Practice
New Definitions, Classification and the Updated Diagnostic Pathway
GDMT Sequencing and Rapid Up-Titration: From STRONG-HF to Routine Care
Foundational Therapy Across the Ejection-Fraction Spectrum
GDMT and Device Therapies
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 2 - HFrEF in 2026: Beyond the Four Pillars
The Four Pillars in Real-World Practice: Are We Actually There Yet?
Digitoxin After DIGIT-HF: Back on the Table?
Vericiguat After VICTOR: Who Benefits, and When?
HFimpEF: Recovery, Remission and the Case for (Not) Withdrawing Therapy
Panel Discussion
Meet the Expert
Meet The Expert
Meet the Expert
Meet The Expert
Plenary Session
Session 3 - Cardiorenal Syndrome in 2026
Beyond eGFR: Assessing and Monitoring Kidney Risk in Heart Failure
Chronic Kidney Disease in HF: Managing the Overlap
Hyperkalaemia as a Barrier to Guideline-Directed Therapy
Potassium Binders and Finerenone: Enabling and Protecting RAAS/MRA Therapy
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 4 - HFpEF: One Syndrome, Many Phenotypes
Finding HFpEF Earlier: Diagnostic Algorithms and Risk Scores
Foundational Therapy in HFpEF: SGLT2 Inhibitors and Finerenone (FINEARTS-HF)
AF-Dominant HFpEF: Rhythm Control, Ablation and the Atrial Myopathy
Arrhythmias in HFpEF
Panel Discussion
Meet the Expert
Meet The Expert
Meet the Expert
Meet The Expert
Plenary Session
Session 5 - CKM Disease and Heart Failure- Obesity is Everywhere
AHA ACC CKM Guidelines
Obesity-Related Heart Failure: Mechanisms and Epidemiology
The Pipeline: Oral GLP-1, Dual and Triple Agonists
Weight Loss, Muscle and Body Composition: Protecting the Muscle
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 6 - Cardiomyopathies and Cardiac Amyloidosis in 2026
A Rational Diagnostic Pathway for the Cardiomyopathies
Cardiac Amyloidosis: When to Suspect and How to Confirm
ATTR-CM Therapies: Stabilisers, Silencers and What Comes Next
Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors in Practice
Panel Discussion
Day 2
Meet the Expert
Meet The Expert
Plenary Session
Session 7 - Rhythm Management and Device Therapies in Heart Failure
Sudden Cardiac Death Prevention in HFrEF: Is the ICD Still Needed in 2026?
CRT and Conduction System Pacing: Choosing the Right Strategy
Cardiac Contractility Modulation and Device-Based Neuromodulation
Interatrial Shunt Devices and Sleep-Disordered Breathing: Where Do They Fit?
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 8 - Valvular Heart Disease and Heart Failure
Functional Mitral Regurgitation: TEER and the Evolving Evidence
Tricuspid Regurgitation in HF: Repair, Replacement or Medical Therapy
Aortic Stenosis and HF: Getting TAVI Timing Right
The Heart Team Approach to the Heart Failure Patient
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 9 - Significant Problem of Vulnerable HF patient
Optimizing Heart Failure Care in Older Patients
Iron Deficiency Across the EF Spectrum: FAIR-HF2 and the Meta-Analytic Picture
Advanced HF: Recognising the Tipping Point and Getting Referral Timing Right
LVAD and Transplant in the Modern Era: Candidacy and Outcomes
Panel Discussion
Meet the Expert
Meet The Expert
Plenary Session
Session 10 - Delivering Better Heart Failure Care and Innovation in 2026
Telemonitoring and Remote Management: What Works and for Whom
Polypharmacy, Adherence and Persistence: The Implementation Reality
Multidisciplinary HF Care and Transitions of Care
Preventing Heart Failure
Panel Discussion
Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
Translate the findings of recent studies and guidelines into optimal patient management
Heart Failure Specialists
General Cardiologists
General Practitioners (GPs)
Nephrologists
Diabetologists / Endocrinologists
Pharmacists and Other Allied Healthcare Professionals
If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com
About Translational Medicine Academy
Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients. Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations. For more information on TMA, please visit www.tmacademy.org.
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community
We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.
We bring medical knowledge to life
From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.
Our work is underpinned by 3 core principles:
We build on the best science
We work hands-on with our community
We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.
For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com